Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions

Blood

Volumn 124, Issue 26, 2014, Pages 3991-3995

  Levade, Marie ^a,b   David, Elodie ^b   Garcia, Cédric ^b   Laurent, Pierre Alexandre ^a   Cadot, Sarah ^b   Michallet, Anne Sophie ^c   Bordet, Jean Claude ^d   Tam, Constantine ^e   Sié, Pierre ^a,b   Ysebaert, Loïc ^f   Payrastre, Bernard ^a,b  

^a University Hospital of Toulouse   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c CENTRE HOSPITALIER LYON SUD   (France)

^d HOSPICES CIVILS DE LYON   (France)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

^f Laboratoire de Biologie Médicale Oncologique   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN VI; IBRUTINIB; VON WILLEBRAND FACTOR; COLLAGEN; DIMETHYL SULFOXIDE; ENZYME INHIBITOR; HEPARIN; PHOSPHOLIPASE C GAMMA; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ARTERY BLOOD FLOW; ARTICLE; BLEEDING; BLEEDING TENDENCY; CLINICAL ARTICLE; EPISTAXIS; EX VIVO STUDY; HEMOSTASIS; HUMAN; IN VITRO STUDY; LONGITUDINAL STUDY; SHEAR RATE; SIGNAL TRANSDUCTION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE RICH PLASMA; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; PHOSPHORYLATION; SHEAR STRENGTH; THROMBOCYTE; THROMBOCYTE ACTIVATION;

BLOOD PLATELETS; COLLAGEN; DIMETHYL SULFOXIDE; ENZYME INHIBITORS; HEMOSTASIS; HEPARIN; HUMANS; LONGITUDINAL STUDIES; PHOSPHOLIPASE C GAMMA; PHOSPHORYLATION; PLATELET ACTIVATION; PLATELET ADHESIVENESS; PYRAZOLES; PYRIMIDINES; SHEAR STRENGTH; VON WILLEBRAND FACTOR;

EID: 84919494922     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-06-583294     Document Type: Article

References (21)

1. Ponader S, Chen S-S, Buggy JJ, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119(5):1182-1189.
2. Herman SEM, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117(23):6287-6296.
3. Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107(29):13075-13080.
4. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42.
5. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507-516.
6. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31(1):88-94.
7. Bhatt V, Alejandro L, Michael A, Ganetsky A. The promising impact of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the management of lymphoid malignancies. Pharmacotherapy. 2014;34(3):303-314.
8. Novero A, Ravella PM, Chen Y, Dous G, Liu D. Ibrutinib for B cell malignancies. Exp Hematol Oncol. 2014;3(1):4.
9. Quek LS, Bolen J, Watson SP. A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen. Curr Biol. 1998;8(20):1137-1140.
10. Atkinson BT, Ellmeier W, Watson SP. Tec regulates platelet activation by GPVI in the absence of Btk. Blood. 2003;102(10):3592-3599.
11. Liu J, Fitzgerald ME, Berndt MC, Jackson CW, Gartner TK. Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo. Blood. 2006;108(8):2596-2603.
12. Gratacap M-P, Martin V, Valéra M-C, et al. The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. Blood. 2009;114(9):1884-1892.
13. Cheng S, Ma J, Guo A, et al. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia. 2014;28(3):649-657.
14. Suzuki-Inoue K, Wilde JI, Andrews RK, et al. Glycoproteins VI and Ib-IX-V stimulate tyrosine phosphorylation of tyrosine kinase Syk and phospholipase Cgamma2 at distinct sites. Biochem J. 2004;378(Pt 3):1023-1029.
15. Yuan Y, Kulkarni S, Ulsemer P, et al. The von Willebrand factor-glycoprotein Ib/V/IX interaction induces actin polymerization and cytoskeletal reorganization in rolling platelets and glycoprotein Ib/V/IX-transfected cells. J Biol Chem. 1999;274(51):36241-36251.
16. Rushworth SA, MacEwan DJ, Bowles KM. Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(13):1277-1278.
17. Byrd JC, O'Brien S, James DF. Ibrutininb in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:1277-1279.
18. Winkelstein JA, Marino MC, Lederman HM, et al. X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine (Baltimore). 2006;85(4):193-202.
19. Qiao J, Schoenwaelder SM, Mason KD, et al. Low adhesion receptor levels on circulating platelets in patients with lymphoproliferative diseases before receiving Navitoclax (ABT-263). Blood. 2013;121(8):1479-1481.
20. Byrd JC, Brown JR, O'Brien S, et al; RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213-223.
21. Kamel S, Horton L, Ysebaert L, et al. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation [published online ahead of print August 20, 2014]. Leukemia. doi:10.1038/leu.2014.247.